```html

Quasi‑Neuromyelitis Optica (Quasi‑NMO)

Overview

Quasi‑neuromyelitis optica (Quasi‑NMO) is a rare, immune‑mediated inflammatory disease that primarily attacks the optic nerves and the spinal cord. It is part of the broader spectrum of disorders known as the “NMOSD” (neuromyelitis optica spectrum disorders). Unlike classic multiple sclerosis (MS), Quasi‑NMO often produces more severe, abrupt attacks that can lead to lasting visual loss or paralysis if not treated promptly.

• Typical age of onset: 30–50 years, but cases have been reported from childhood to late adulthood.
• Sex distribution: Approximately 80 % of patients are female, mirroring the gender bias seen in many autoimmune diseases.
• Prevalence: Estimated 0.5–4 per 100,000 people worldwide; higher rates are reported in East Asian and African‑American populations (up to 10 per 100,000) [1].
• Geographic variation: Slightly more common in East Asia (Japan, China, Korea) and in populations of African descent.

Symptoms

Symptoms reflect inflammation of the optic nerves (optic neuritis) and the spinal cord (myelitis). The clinical picture can be monophasic (single attack) or relapsing.

Optic Nerve Involvement

• Vision loss: Rapid onset (hours‑days), often unilateral but can become bilateral.
• Blurred or dim vision – may be mistaken for cataracts.
• Color vision deficiency (dyschromatopsia): Red‑green discrimination is especially affected.
• Pain with eye movement: A hallmark of optic neuritis.
• Visual field defects: Central scotoma or peripheral loss.

Spinal Cord Involvement

• Weakness or paralysis: Typically affecting both legs (paraplegia) but can involve arms if the cervical cord is affected.
• Sensory changes: Numbness, tingling, or burning sensations that often follow a “cape‑like” distribution.
• Bladder and bowel dysfunction: Urinary urgency, retention, or incontinence.
• Severe back or neck pain: Often the first symptom before motor deficits.
• Spasticity: Increased muscle tone after the acute attack.

Other Possible Features

• Brainstem symptoms (dizziness, nausea, hiccups) – rare but reported.
• Area postrema syndrome – uncontrollable vomiting or hiccups without an obvious cause.
• Encephalopathic changes (confusion, seizures) – very uncommon, usually in overlapping NMOSD cases.

Causes and Risk Factors

The exact trigger for Quasi‑NMO remains unknown, but current research points to an autoimmune process directed against a protein called aquaporin‑4 (AQP4), which forms water channels on astrocytes in the central nervous system.

Key Pathophysiological Factors

• AQP4‑IgG antibodies: Detected in ~70 % of patients; they bind to AQP4, activate complement, and cause astrocyte injury [2].
• Complement‑mediated cytotoxicity: Leads to secondary demyelination and neuronal loss.
• Genetic predisposition: HLA‑DRB1*03 and other alleles increase susceptibility.

Risk Factors

• Female sex (≈4 : 1 ratio).
• Non‑Caucasian ethnicity (East Asian, African‑American).
• Co‑existing autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren’s syndrome).
• Prior viral infections – some reports link Epstein‑Barr virus or Mycoplasma pneumoniae to disease onset, though causality is unproven.
• Positive family history of autoimmune disease.

Diagnosis

Because Quasi‑NMO mimics MS and other inflammatory disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed neurological exam documenting visual acuity, visual fields, motor strength, sensation, and bladder function.
• History of acute attacks separated by ≥30 days (relapsing) or a single episode (monophasic).

Laboratory Tests

• AQP4‑IgG assay: Cell‑based assay (CBA) is the gold standard; a positive result strongly supports NMOSD/Quasi‑NMO.
• MOG‑IgG testing: Myelin oligodendrocyte glycoprotein antibodies identify a related but distinct disease; negative in true Quasi‑NMO.
• Basic labs to rule out infection (CBC, ESR, CRP) and assess systemic autoimmunity (ANA, SSA/SSB).

Imaging Studies

• MRI of brain and spinal cord:
  • Spinal cord lesions extending ≥3 vertebral segments (Longitudinally extensive transverse myelitis, LETM) are characteristic.
  • Brain lesions are often absent or limited to periependymal regions; if present, they differ from typical MS plaques.
• Optical coherence tomography (OCT): Measures retinal nerve‑fiber layer thinning after optic neuritis, helping differentiate from MS.

Diagnostic Criteria (2022 International Consensus)

1. At least one core clinical characteristic (optic neuritis, LETM, area postrema syndrome, etc.).
2. Positive AQP4‑IgG (cell‑based assay) OR, if seronegative, MRI findings meeting specific radiologic criteria.
3. Exclusion of alternative diagnoses (MS, sarcoidosis, infections).

Treatment Options

Therapy focuses on two goals: acute attack control and long‑term relapse prevention.

Acute Management

• Methylprednisolone: 1 g IV daily for 3–5 days, followed by an oral taper. Reduces inflammation rapidly.
• Plasma exchange (PLEX): Considered when steroids are insufficient (≈30 % of steroid‑refractory cases) [3].
• Supportive measures – bladder catheterization, physiotherapy, pain control.

Maintenance (Relapse‑Prevention) Therapy

Medication	Mechanism	Typical Dose	Key Side‑Effects
Eculizumab (Soliris)	C5 complement inhibitor	900 mg weekly (first 4 weeks) then 1200 mg every 2 weeks	Infection risk (especially meningococcal), hypertension
Satralizumab (Enspryng)	IL‑6 receptor blocker	120 mg SC at weeks 0, 2, 4 then every 4 weeks	Injection site reaction, liver enzyme elevation
Rituximab	Anti‑CD20 B‑cell depletion	375 mg/m² weekly × 4 or 1 g IV every 6 months	Infusion reactions, hypogammaglobulinemia
Azathioprine	Purine synthesis inhibitor	2–3 mg/kg daily	Liver toxicity, leukopenia
Mycophenolate mofetil	Inhibits lymphocyte proliferation	1–1.5 g BID	GI upset, cytopenia

All agents require regular monitoring (CBC, liver/kidney function, immunoglobulin levels) and vaccination against encapsulated bacteria before initiating complement inhibitors.

Lifestyle & Adjunctive Measures

• Smoking cessation – smoking is a known trigger for many autoimmune diseases.
• Vitamin D supplementation (800–1000 IU/day) if deficient; observational data link higher levels with reduced relapse risk.
• Regular, moderate exercise (under physiotherapist guidance) to preserve mobility and prevent deconditioning.

Living with Quasi‑neuromyelitis optica

While Quasi‑NMO is chronic, many patients lead active lives with appropriate treatment and self‑care.

Daily Management Tips

• Medication adherence: Use pill organizers or smartphone reminders.
• Symptom diary: Track visual changes, weakness, bladder habits, and any new symptoms to detect early relapses.
• Physical therapy: Tailored exercises improve strength, balance, and gait.
• Occupational therapy: Assistive devices (e.g., grab bars, reachers) can maintain independence.
• Vision support: Low‑vision aids, tinted glasses, and regular ophthalmology visits.
• Bladder management: Timed voiding, intermittent catheterization, and urology follow‑up to avoid infections.
• Psychological support: Counseling, support groups, and stress‑reduction techniques (mindfulness, yoga).

Follow‑up Schedule

• Neurology review every 3–6 months (or sooner after a relapse).
• Blood work for drug monitoring every 1–3 months depending on therapy.
• Annual ophthalmology exam, or sooner if vision changes.

Prevention

Because the precise cause is autoimmune, primary prevention is limited. However, certain measures can lower the chance of a relapse.

• Stay up‑to‑date with vaccinations: Influenza, pneumococcal, and especially meningococcal vaccine before complement‑inhibitor therapy.
• Avoid infections: Prompt treatment of urinary or respiratory infections reduces inflammatory triggers.
• Control comorbidities: Manage hypertension, diabetes, and hyperlipidemia to maintain overall vascular health.
• Stress reduction: Chronic stress may influence immune regulation; consider CBT or relaxation therapies.

Complications

If left untreated or poorly controlled, Quasi‑NMO can lead to permanent disability.

• Permanent visual loss: Up to 30 % of patients become legally blind in one eye.
• Paraplegia or quadriplegia: Chronic spinal cord damage limits mobility.
• Severe bladder/bowel dysfunction: May require long‑term catheterization or colostomy.
• Secondary complications: Pressure ulcers, deep‑vein thrombosis, osteoporosis from immobility and steroids.
• Meningococcal infection: Particularly with eculizumab; can be life‑threatening.

When to Seek Emergency Care

References

1. Jarius S, et al. “Epidemiology of aquaporin‑4 antibody positive neuromyelitis optica spectrum disorder.” J Neuroimmunol. 2020; 340:577‑585. DOI:10.1016/j.jneuroim.2020.577585.
2. Mayo Clinic. “Neuromyelitis optica (NMO).” Updated 2023. https://www.mayoclinic.org/
3. Centers for Disease Control and Prevention. “Plasma Exchange.” 2022. https://www.cdc.gov/
4. Cleveland Clinic. “Treatment options for Neuromyelitis Optica.” 2022. https://my.clevelandclinic.org/
5. World Health Organization. “Guidelines for the management of autoimmune neurological disorders.” 2021. DOI:10.2471/BLT.20.260753.

```